New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:03 EDTCNATConatus initiates emricasan Phase 2b trial
Conatus Pharmaceuticals announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection who have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. The placebo-controlled, double-blind trial is designed to enroll approximately 60 patients at approximately 15 planned U.S. clinical sites. Enrollment is expected to take approximately 12 months. Patients will be randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will then be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. The sponsor-open design may allow for interim data analyses and periodic disclosures on trial progress.
News For CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
16:05 EDTCNATConatus announces acceptance of abstracts for AASLD annual meeting
Conatus Pharmaceuticals announced that abstracts for two posters addressing preclinical results with the company's pan-caspase inhibitors, have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, or AASLD, in San Francisco November 13-17. Accepted abstracts were published today on the AASLD website at for posters entitled, "Alcohol stimulates macrophage activation through caspase dependent, hepatocyte derived release of CD40L containing extracellular vesicles," and "Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of long-term common bile-duct ligation."
September 25, 2015
12:13 EDTCNATConatus management to meet with SunTrust
Subscribe for More Information
September 24, 2015
13:38 EDTCNATConatus mentioned positively at Brean Capital
10:13 EDTCNATHigh option volume stocks
Subscribe for More Information
09:05 EDTCNATOn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
06:36 EDTCNATConatus to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use